TORONTO, Feb. 3 /PRNewswire-FirstCall/ -- Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, today announced that the company is actively investing in its growing healthcare division, enhancing its customized network to help healthcare OEMs accelerate their success. Building upon the company's extensive experience in servicing highly regulated industries with complex technology solutions, Celestica continues to make strategic investments to further tailor its offering to healthcare customers. These investments include expanding capabilities and industry expertise. "Today's healthcare companies need partners who are prepared to invest in their success and who can deliver customized solutions to help them accelerate results," said Craig Muhlhauser, President and Chief Executive Officer, Celestica. "Our approach is to collaborate with our healthcare customers to deliver new and innovative supply chain solutions designed specifically for the healthcare industry of the future." Celestica continues to advance its healthcare capabilities within its 13485-certified, global healthcare network. The company has invested more than $2.8 million to establish a metrology laboratory in its Suzhou, China facility. The site also has a Class 1,000 (ISO Class 3) ISO 14644-1 certified clean room, providing customers with state-of-the-art service technology in this important region. To further enhance the company's expertise in the healthcare segment, Celestica is also announcing three new appointments in this division. The new appointments include: Nancy Duarte-Lonnroth, Director of Quality, Regulatory Affairs; Richard Rubin, Director of Market Development; and Michael Sobolewski, Director of Sales and Business Development. These appointments will support Sandra Ketchen, Vice President, Healthcare, as she drives the growth and strategic direction for the division. Duarte-Lonnroth joins the Celestica healthcare team with 15 years of experience in various senior quality and compliance roles with organizations such as Acusphere, Histogenics, Stryker Biotech, Alkermes, Armstrong Pharmaceuticals and Hygeia Proscience. Rubin has more than 25 years of experience in biomedical laboratory instrumentation and in-vitro diagnostic systems manufacturing. He brings to the Celestica healthcare team exceptional expertise in all aspects of the medical device marketplace. Sobolewski brings extensive clinical and practical experience in healthcare and medical device design and manufacturing services. Prior to joining Celestica, he spent 18 years working with electronics manufacturing services companies in a variety of senior roles. "In today's patient-centric market, healthcare technology providers need to invest in innovation to stay competitive amid increasing pressure to manage product costs," said Sandra Ketchen, Vice President, Healthcare, Celestica. "With a relentless focus on quality and compliance, we help medical equipment companies focus on core activities, improve their time-to-market, lower manufacturing costs and mitigate risk." Celestica's healthcare division provides design, automated manufacturing, electronics manufacturing, fulfillment and after-market services to medical equipment companies. The company operates an ISO 9001/13485 Certified, QSR compliant network and is a U.S. FDA-registered manufacturer of medical devices. About Celestica Celestica is dedicated to delivering end-to-end product lifecycle solutions to drive our customers' success. Through our simplified global operations network and information technology platform, we are solid partners who deliver informed, flexible solutions that enable our customers to succeed in the markets they serve. Committed to providing a truly differentiated customer experience, our agile and adaptive employees share a proud history of demonstrated expertise and creativity that provides our customers with the ability to overcome any challenge. For further information on Celestica, visit its website at http://www.celestica.com/ The company's security filings can also be accessed at http://www.sedar.com/ and http://www.sec.gov/. Safe Harbour and Fair Disclosure Statement Statements contained in this press release which are not historical facts are forward-looking statements. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forward-looking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions, or may employ such future or conditional verbs as "may", "will", "should," or "would," or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and in any applicable Canadian securities legislation. Forward looking statements are not guarantees of future performance. Risks and uncertainties, as well as other information related to the Company, are discussed in the Company's various public filings at http://www.sedar.com/ and http://www.sec.gov/, including our Annual Report on Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission and our Annual Information Form filed with the Canadian Securities Commissions. Forward-looking statements are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. DATASOURCE: Celestica Inc. CONTACT: Pam White, Celestica Global Communications, (416) 448-4735,

Copyright